{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T22:52:31Z","timestamp":1767135151202,"version":"build-2238731810"},"update-to":[{"DOI":"10.1002\/14651858.cd010509","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2014,9,19]],"date-time":"2014-09-19T00:00:00Z","timestamp":1411084800000}}],"reference-count":185,"publisher":"Wiley","issue":"4","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd010509.pub2","type":"journal-article","created":{"date-parts":[[2014,9,19]],"date-time":"2014-09-19T07:40:20Z","timestamp":1411112420000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Aclidinium bromide for stable chronic obstructive pulmonary disease"],"prefix":"10.1002","volume":"2015","author":[{"given":"Han","family":"Ni","sequence":"first","affiliation":[{"name":"SEGi University; Internal Medicine; Hospital Teluk Intan Jalan Changkat Jong Teluk Intan Perak Darul Ridzuan Malaysia 36000"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zay","family":"Soe","sequence":"additional","affiliation":[{"name":"UCSI University; Internal Medicine; Terengganu Malaysia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soe","family":"Moe","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Melaka-Manipal Medical College; Department of Community Medicine; Jalan Batu Hampar Bukit Baru Melaka Malaysia 75150"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,9,19]]},"reference":[{"key":"10.1002\/14651858.CD010509.pub2-BIB0001|cit1","unstructured":"EUCTR2005-005101-39-AT A 52-week randomised, double-blind, parallel group, placebo controlled, multicentre clinical trial, to assess the efficacy and safety of 200 \u00b5g of the anticholinergic LAS 34273 compared to placebo, both administered once daily by inhalation, in the maintenance treatment of patients with moderate to severe, stable chronic obstructive pulmonary disease https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2005-005101-39"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0002|cit2","doi-asserted-by":"crossref","unstructured":"Jones PW Agusti A Chanez P Magnussen H Fabbri L Maroni J A phase III study evaluating aclidinium bromide, a novel long-acting antimuscarinic in patients with COPD: ACCLAIM\/COPD 1 [Abstract] American Thoracic Society International Conference; May 15-20; San Diego 2009 A6180 [Poster #207]","DOI":"10.1164\/ajrccm-conference.2009.179.1_MeetingAbstracts.A6180"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0003|cit3","unstructured":"Jones PW Agusti A Chanez P Magnussen H Fabbri L Maroni J Efficacy and safety of aclidinium bromide, a novel long-acting muscarinic antagonist, in patients with moderate to severe COPD [Abstract] European Respiratory Society Annual Congress; Sep 12-16; Vienna 2009 [P2022]"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0004|cit4","first-page":"A168 [P213]","article-title":"A phase III study evaluating aclidinium bromide, a novel long-acting antimuscarinic, in patients with COPD: ACCLAIM\/COPD I [Abstract]","volume":"64 Suppl IV","author":"Jones","year":"2009","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1465-9921-12-55","article-title":"Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease","volume":"12","author":"Jones","year":"2011","journal-title":"Respiratory Research"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0006|cit6","unstructured":"NCT00363896 A trial assessing LAS34273 in moderate to severe stable chronic obstructive pulmonary disease (COPD) http:\/\/www.clinicaltrials.gov\/ct2\/show\/study\/NCT00363896"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1465-9921-12-55","article-title":"Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease","volume":"12","author":"Jones","year":"2011","journal-title":"Respiratory Research"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0008|cit8","unstructured":"NCT00358436 Efficacy and safety of LAS 34273 in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD) http:\/\/www.clinicaltrials.gov\/ct2\/show\/study\/NCT00358436"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0009|cit9","doi-asserted-by":"crossref","unstructured":"Rennard S Donohue J Bateman E Gross N Garcia Gil E Caracta C ACCLAIM\/COPD II: efficacy and safety of aclidinium bromide; a novel long-acting muscarinic antagonist in COPD patients, a phase III study [Abstract] European Respiratory Society Annual Congress Sep 12-16; Vienna 2009 [E4351]","DOI":"10.1164\/ajrccm-conference.2009.179.1_MeetingAbstracts.A6178"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0010|cit10","doi-asserted-by":"crossref","unstructured":"Rennard S Donohue J Bateman E Gross N Garcia Gil E Caracta C Efficacy and safety of the novel, long-acting antimuscarinic, aclidinium bromide, in COPD patients in a phase III study: ACCLAIM\/COPD II [Abstract] American Thoracic Society International Conference; May 15-20; San Diego 2009 A6178 [Poster #205]","DOI":"10.1164\/ajrccm-conference.2009.179.1_MeetingAbstracts.A6178"},{"issue":"Meeting Abstrac","key":"10.1002\/14651858.CD010509.pub2-BIB0012|cit11","first-page":"A1614","article-title":"Safety and tolerability of twice daily aclidinium bromide in COPD patients: ACCORD COPD I [Abstract]","volume":"183","author":"D'Urzo","year":"2011","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0011|cit12","doi-asserted-by":"crossref","unstructured":"D\u2019Urzo A Make B Kerwin E Rekeda L Garcia Gil E Caracta C ACCORD COPD I: Safety and tolerability of twice daily aclidinium bromide in COPD patients [Abstract] European Respiratory Society Annual Congress; Sep 24-28; Amsterdam 2011 729s [P3998]","DOI":"10.1164\/ajrccm-conference.2011.183.1_MeetingAbstracts.A1614"},{"issue":"55","key":"10.1002\/14651858.CD010509.pub2-BIB0013|cit13","first-page":"149s [P876]","article-title":"ACCORD COPD I: Twice-daily aclidinium bromide improves quality of life and dyspnea in COPD patients [Abstract]","volume":"38","author":"Gelb","year":"2011","journal-title":"European Respiratory Society Annual Congress; Sep 24-28; Amsterdam"},{"issue":"Meeting Abstrac","key":"10.1002\/14651858.CD010509.pub2-BIB0014|cit14","first-page":"A1616","article-title":"Improvements in quality of life and dyspnea in COPD patients with twice-daily aclidinium [Abstract]","volume":"183","author":"Gelb","year":"2011","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0016|cit15","doi-asserted-by":"crossref","unstructured":"Kerwin E D'Urzo A Gelb A Lakkis H Garcia Gil E Caracta C Twice-daily aclidinium bromide in COPD patients: Efficacy and safety results from ACCORD COPD I [Abstract] European Respiratory Society Annual Congress; Sep 18-22; Barcelona 2010 [P1235]","DOI":"10.1378\/chest.10344"},{"issue":"4","key":"10.1002\/14651858.CD010509.pub2-BIB0015|cit16","doi-asserted-by":"crossref","first-page":"469A","DOI":"10.1378\/chest.10344","article-title":"Efficacy and safety of twice-daily aclidinium bromide in patients with COPD: results from ACCORD COPD 1 [Abstract]","volume":"138","author":"Kerwin","year":"2010","journal-title":"Chest"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0017|cit17","unstructured":"Kerwin E Rennard S Gelb A Rekeda L Garcia Gil E Caracta C ACCORD COPD I: Improvements in nighttime symptoms and rescue medication use in COPD with twice-daily aclidinium bromide [Abstract] European Respiratory Society Annual Congress; Sep 24-28; Amsterdam 2011 149s [P873]"},{"issue":"2","key":"10.1002\/14651858.CD010509.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3109\/15412555.2012.661492","article-title":"Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I)","volume":"9","author":"Kerwin","year":"2012","journal-title":"COPD"},{"issue":"Meeting Abstrac","key":"10.1002\/14651858.CD010509.pub2-BIB0019|cit19","first-page":"A1592","article-title":"Twice-daily aclidinium bromide in COPD patients: nighttime symptoms and rescue medication use in ACCORD COPD I [Abstract]","volume":"183","author":"Kerwin","year":"2011","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0020|cit20","unstructured":"NCT00891462 Efficacy and safety of aclidinium bromide for treatment of moderate to severe chronic obstructive pulmonary disease (COPD) (LAS-MD-33) http:\/\/www.clinicaltrials.gov\/ct2\/show\/study\/NCT00891462"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0021|cit21","unstructured":"NCT01045161 To assess the long-term safety, efficacy and tolerability of inhaled aclidinium bromide in the treatment of moderate-to-severe chronic obstructive pulmonary disease (COPD) (LAS-MD-38) http:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT01045161"},{"issue":"12","key":"10.1002\/14651858.CD010509.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s40261-013-0138-1","article-title":"ACCORD COPD II: A randomised clinical trial to evaluate the 12-week efficacy and safety of twice-daily aclidinium bromide in chronic obstructive pulmonary disease patients","volume":"33","author":"Rennard","year":"2013","journal-title":"Clinical Drug Investigation"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0023|cit23","unstructured":"EUCTR2011-001524-38-GB Efficacy and safety of aclidinium bromide\/formoterol fumarate fixed-dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2011-001524-38"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0024|cit24","unstructured":"NCT01462942 Long-term efficacy and safety of aclidinium\/formoterol fixed-dose combination http:\/\/clinicaltrials.gov\/show\/NCT01462942"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"375A","DOI":"10.1378\/chest.1796046","article-title":"Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed-dose combination in patients with COPD: the ACLIFORM study","volume":"145","author":"Singh","year":"2014","journal-title":"Chest"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0026|cit26","unstructured":"Agusti A Jones PW Bateman E Singh D Lamarca R de Miquel G Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: results from ATTAIN [Abstract] European Respiratory Society Annual Congress; Sep 24-28; Amsterdam 2011 149s [P874]"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0027|cit27","unstructured":"Bateman ED Singh D Jones PW Agusti A Lamarca R de Miquel G The ATTAIN study: safety and tolerability of aclidinium bromide in chronic obstructive pulmonary disease [Abstract] European Respiratory Society Annual Congress; Sep 24-28; Amsterdam 2011 730s [P4005]"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0028|cit28","unstructured":"EUCTR2009-011600-27-CZ Efficacy and safety of aclidinium bromide at two dose levels vs placebo when administered to patients with moderate to severe chronic obstructive pulmonary disease (COPD) https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2009-011600-27"},{"issue":"4","key":"10.1002\/14651858.CD010509.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"529A","DOI":"10.1378\/chest.1111458","article-title":"Aclidinium bromide in patients with chronic obstructive pulmonary disease (COPD): Reduction in exacerbations as defined by health-care utilisation and the EXACT diary card [Abstract]","volume":"140","author":"Jones","year":"2011","journal-title":"Chest"},{"issue":"4","key":"10.1002\/14651858.CD010509.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"547A","DOI":"10.1378\/chest.1119097","article-title":"Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in symptoms and health status in the ATTAIN Study [Abstract]","volume":"140","author":"Jones","year":"2011","journal-title":"Chest"},{"issue":"4","key":"10.1002\/14651858.CD010509.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"975A","DOI":"10.1378\/chest.1111549","article-title":"ATTAIN: Efficacy and safety of twice-daily aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]","volume":"140","author":"Jones","year":"2011","journal-title":"Chest"},{"issue":"Meeting Abstrac","key":"10.1002\/14651858.CD010509.pub2-BIB0032|cit32","first-page":"A6350","article-title":"Aclidinium bromide in patients with chronic obstructive pulmonary disease: Efficacy and safety results from ATTAIN [Abstract]","volume":"183","author":"Jones","year":"2011","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"55","key":"10.1002\/14651858.CD010509.pub2-BIB0033|cit33","first-page":"150s [P877]","article-title":"Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in health status in ATTAIN [Abstract]","volume":"38","author":"Jones","year":"2011","journal-title":"European Respiratory Society Annual Congress, Amsterdam, The Netherlands, September 24-28"},{"issue":"Meeting abstrac","key":"10.1002\/14651858.CD010509.pub2-BIB0034|cit34","first-page":"A6072","article-title":"Unreported exacerbations of chronic obstructive pulmonary disease are associated with a reduction in health status: results from the ATTAIN study","volume":"187","author":"Jones","year":"2013","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0035|cit35","unstructured":"Jones PW Singh D Agusti A Bateman ED Lamarca R de Miquel G Aclidinium bromide reduces COPD exacerbations as defined by healthcare utilisation and EXACT: results from ATTAIN [Abstract] European Respiratory Society Annual Congress, Vienna, Austria, September 1-5 2012 9s [195]"},{"issue":"4","key":"10.1002\/14651858.CD010509.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1183\/09031936.00225511","article-title":"Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study","volume":"40","author":"Jones","year":"2012","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0037|cit37","unstructured":"NCT01001494 Efficacy and safety of aclidinium bromide at two dose levels versus placebo administered in chronic obstructive pulmonary disease (COPD) patients http:\/\/www.clinicaltrials.gov\/ct2\/show\/study\/NCT01001494"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0038|cit38","unstructured":"Singh D Bateman ED Jones PW Agusti A Lamarca R de Miquel G The ATTAIN study: bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract] European Respiratory Society Annual Congress; Sep 24-28; Amsterdam 2011 149s [P875]"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0039|cit39","first-page":"A171 [P255]","article-title":"ATTAIN: Twice-daily aclidinium bromide in patients with moderate to severe chronic obstructive pulmonary disease [Abstract]","volume":"66 Suppl 4","author":"Singh","year":"2011","journal-title":"Thorax"},{"issue":"4","key":"10.1002\/14651858.CD010509.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"1025A","DOI":"10.1378\/chest.1780390","article-title":"Efficacy and safety of fixed-dose combination aclidinium bromide\/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial","volume":"144","author":"D'Urzo","year":"2013","journal-title":"Chest"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"426A","DOI":"10.1378\/chest.1821799","article-title":"The AUGMENT COPD trial: efficacy and safety of a fixed-dose combination of aclidinium bromide and formoterol fumarate in COPD patients","volume":"145","author":"D'Urzo","year":"2014","journal-title":"Chest"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0042|cit42","unstructured":"NCT01437397 Efficacy, safety and tolerability of aclidinium bromide\/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC) http:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT01437397"},{"issue":"Meeting Abstrac","key":"10.1002\/14651858.CD010509.pub2-BIB0045|cit43","first-page":"A4253","article-title":"Efficacy and safety of aclidinium bromide compared with tiotropium and placebo in patients with moderate-to-severe COPD: a phase IIIb study","volume":"187","author":"Beier","year":"2013","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0046|cit44","first-page":"A26 [S51]","article-title":"Efficacy of aclidinium bromide compared with tiotropium and placebo in patients with moderate to severe COPD: a phase IIIb study [Abstract]","volume":"67 Suppl 2","author":"Beier","year":"2012","journal-title":"Thorax"},{"issue":"Meeting Abstrac","key":"10.1002\/14651858.CD010509.pub2-BIB0047|cit45","first-page":"A4276","article-title":"Improvements in COPD symptoms and rescue medication use with aclidinium bromide compared with tiotropium and placebo: a phase IIIb study","volume":"187","author":"Beier","year":"2013","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"4","key":"10.1002\/14651858.CD010509.pub2-BIB0048|cit46","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3109\/15412555.2013.814626","article-title":"Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a six-week, randomised, controlled phase IIIb study","volume":"10","author":"Beier","year":"2013","journal-title":"COPD"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0043|cit47","unstructured":"Beier J Kirsten AM Mr\u00f3z R Segarra R Chuecos F Caracta C Efficacy and safety of aclidinium bromide vs placebo and tiotropium in COPD: a phase IIIb study [Abstract] European Respiratory Society Annual Congress; Sep 7-11; Barcelona 2013 4s [185]"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0044|cit48","unstructured":"Beier J Kirsten AM Mr\u00f3z R Segarra R Chuecos F Caracta C Improvement in COPD symptoms with aclidinium bromide vs placebo and tiotropium: A phase IIIb study [Abstract] European Respiratory Society Annual Congress; Sept 7-11; Barcelona 2013 4s [184]"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0049|cit49","unstructured":"EUCTR2011-000834-12-DE A multiple dose, double-blind, double-dummy, placebo controlled, parallel clinical trial to assess the efficacy and safety of twice daily inhaled aclidinium bromide 400 \u00b5g compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD) https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2011-000834-12"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0050|cit50","unstructured":"NCT01462929 Efficacy and safety of aclidinium bromide 400 \u03bcg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD) http:\/\/www.clinicaltrials.gov\/ct2\/show\/study\/NCT01462929"},{"issue":"1","key":"10.1002\/14651858.CD010509.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.pupt.2009.08.001","article-title":"Aclidinium bromide provides long-acting bronchodilation in patients with COPD","volume":"23","author":"Chanez","year":"2010","journal-title":"Pulmonary Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0052|cit52","unstructured":"Chanez P Burge S Dahl R Creemers J Lamarca R Garcia GE Once-daily administration of aclidinium bromide, a novel, long-acting anticholinergic: a phase II, dose-finding study [Abstract] American Thoracic Society International Conference; May 16-21; Toronto 2008 [A286]"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0053|cit53","unstructured":"Charez P Burge S Creemers J Lamarca R Garcia GE Once daily administration of aclidinium bromide a novel long acting anticholinergic a phase II dose finding study [Abstract] European Respiratory Society Annual Congress; Oct 4-8; Berlin 2008 [2736]"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0054|cit54","unstructured":"Casaburi R Maltais F Celli B Porszasz J Garcia Gil E Caracta C Aclidinium bromide improves exercise endurance and decreases exertional dyspnoea in patients with COPD [Abstract] European Respiratory Society Annual Congress, Barcelona, Spain, September 18-22 2010 [5558]"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0055|cit55","unstructured":"Celli B Maltais F Casaburi R Porszasz J Garcia Gil E Caracta C Aclidinium bromide improves resting lung function in patients with moderate to severe COPD [Abstract] European Respiratory Society Annual Congress, Barcelona, Spain, September 18-22 2010 [P1183]"},{"issue":"4","key":"10.1002\/14651858.CD010509.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.rmed.2010.11.019","article-title":"Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD","volume":"105","author":"Maltais","year":"2011","journal-title":"Respiratory Medicine"},{"issue":"Meeting Abstrac","key":"10.1002\/14651858.CD010509.pub2-BIB0057|cit57","first-page":"A4428","article-title":"Aclidinium bromide improves exercise endurance, dyspnea and inspiratory capacity in patients with moderate to severe COPD [Abstract]","volume":"181","author":"Maltais","year":"2010","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0058|cit58","unstructured":"NCT00500318 A study of exercise endurance and lung hyperinflation in patients with moderate to severe chronic obstructive pulmonary disease (COPD) http:\/\/www.clinicaltrials.gov\/ct2\/show\/study\/NCT00500318"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0059|cit59","unstructured":"NCT01572792 Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide\/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28-weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD) http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01572792"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0060|cit60","unstructured":"EUCTR2007-004435-30-CZ A randomised, four-week, placebo-controlled, double-blind, six arm parallel group, dose-finding clinical trial, to assess the efficacy and safety of three different doses of formoterol (6, 12 & 18\u00b5g) combined with the inhaled anticholinergic aclidinium bromide 200 \u00b5g, aclidinium bromide 200 \u00b5g monotherapy and formoterol 12 \u00b5g monotherapy all administered once daily by inhalation via Almirall inhaler in patients with stable moderate to severe chronic obstructive pulmonary disease https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2007-004435-30"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0061|cit61","first-page":"P137","article-title":"Efficacy and safety of once-daily aclidinium bromide 200 \u00b5g in combination with formoterol in patients with COPD [Abstract]","volume":"65 Suppl 4","author":"Sliwinski","year":"2010","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0062|cit62","unstructured":"D'Urzo A Kerwin E Donohue J Rennard S Gelb A Lakkis H Effects of twice-daily aclidinium bromide in COPD patients: A long-term extension of ACCORD-COPD I [Abstract] European Respiratory Society Annual Congress, Sep 1-5; Vienna 2012 528s [P2890]"},{"issue":"4_Meeting abstr","key":"10.1002\/14651858.CD010509.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"740A","DOI":"10.1378\/chest.1381411","article-title":"Improvements in lung function with twice-daily aclidinium bromide: results of a long-term, phase 3 trial in patients with chronic obstructive pulmonary disease [Abstract]","volume":"142","author":"D'Urzo","year":"2012","journal-title":"Chest"},{"issue":"4","key":"10.1002\/14651858.CD010509.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"500","DOI":"10.3109\/15412555.2013.791809","article-title":"One-year extension study of ACCORD COPD I: safety and efficacy of two doses of twice-daily aclidinium bromide in patients with COPD","volume":"10","author":"D'Urzo","year":"2013","journal-title":"COPD"},{"issue":"Meeting Abstrac","key":"10.1002\/14651858.CD010509.pub2-BIB0065|cit65","first-page":"A2913","article-title":"Long-term extension study of ACCORD COPD I: effects of two doses of twice-daily aclidinium bromide in COPD patients [Abstract]","volume":"185","author":"D'Urzo","year":"2012","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"4_Meeting abstr","key":"10.1002\/14651858.CD010509.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"691A","DOI":"10.1378\/chest.1389776","article-title":"Effects of aclidinium bromide in patients with chronic obstructive pulmonary disease: clinically significant improvements in health status in two one-year studies","volume":"142","author":"Gelb","year":"2012","journal-title":"Chest"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0067|cit67","unstructured":"NCT00970268 Long-term extension study of the safety, tolerability, and efficacy of aclidinium bromide in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAS-MD-36) http:\/\/www.clinicaltrials.gov\/ct2\/show\/study\/NCT00970268"},{"issue":"4_Meeting abstr","key":"10.1002\/14651858.CD010509.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"746A","DOI":"10.1378\/chest.1703098","article-title":"Aclidinium bromide improves lung function in a wide range of patients with moderate to severe COPD: Pooled subgroup analysis of the ACCORD COPD I and II and ATTAIN trials","volume":"144","author":"D'Urzo","year":"2013","journal-title":"Chest"},{"issue":"4_Meeting abstr","key":"10.1002\/14651858.CD010509.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"717A","DOI":"10.1378\/chest.1703157","article-title":"Exposure-adjusted anticholinergic adverse events following long-term treatment with aclidinium bromide in patients with COPD","volume":"144","author":"D'Urzo","year":"2013","journal-title":"Chest"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0070|cit70","unstructured":"de Miquel G Schrodter A Miletzki B Gurniak M Serra C Jansat JM Low systematic exposure to aclidinium bromide, a novel long-acting anticholinergic, after multiple doses [Abstract] American Thoracic Society International Conference; May 16-21; Toronto 2008 Poster #F53"},{"issue":"4_Meeting abstr","key":"10.1002\/14651858.CD010509.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"716A","DOI":"10.1378\/chest.1703139","article-title":"Long-term cardiovascular safety of aclidinium bromide in patients with COPD","volume":"144","author":"Donohue","year":"2013","journal-title":"Chest"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0072|cit72","unstructured":"A multiple dose, double-blind, double-dummy, three period cross-over, placebo controlled clinical trial to assess the efficacy and safety of once daily inhaled aclidinium bromide 200 \u00b5g given either in the morning or in the evening in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD) https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2007-000010-36"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0073|cit73","unstructured":"A phase IIa, randomised, multicentre, evaluator-blinded, four-way crossover clinical trial to study the pharmacokinetics, safety, tolerability and effects on lung function of one day treatment of formoterol 12 \u00b5g once daily delivered by two different dry powder inhalers (Aerolizer\u00ae and Almirall inhaler), of the fixed dose combination formoterol 12 \u00b5g + aclidinium bromide 200 \u00b5g once daily delivered by Almirall inhaler, and of formoterol 12 \u00b5g twice daily delivered by Aerolizer\u00ae, in moderate to severe chronic obstructive pulmonary disease patients https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2007-003648-31"},{"issue":"4_Meeting abstr","key":"10.1002\/14651858.CD010509.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"715A","DOI":"10.1378\/chest.1703123","article-title":"Cardiovascular safety of aclidinium bromide in COPD: pooled results from three placebo-controlled studies","volume":"144","author":"Ferguson","year":"2013","journal-title":"Chest"},{"issue":"Meeting Abstrac","key":"10.1002\/14651858.CD010509.pub2-BIB0075|cit75","first-page":"A4463","article-title":"Metabolism and excretion of aclidinium bromide following intravenous administration of [14C] aclidinium bromide in healthy subjects [Abstract]","volume":"181","author":"Flach","year":"2010","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0076|cit76","doi-asserted-by":"crossref","unstructured":"Fuhr R Magnussen H Ribera A Kirsten A Falques M Caracta C Efficacy and safety of twice-daily aclidinium bromide compared with tiotropium and placebo in patients with moderate to severe COPD [Abstract] European Respiratory Society Annual Congress; 2010 September 18-22; Barcelona, Spain 2010 [P1236]","DOI":"10.1378\/chest.9404"},{"issue":"4","key":"10.1002\/14651858.CD010509.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"465A","DOI":"10.1378\/chest.9404","article-title":"Efficacy and safety of twice-daily aclidinium bromide 400 \u00b5g compared with placebo and tiotropium 18 \u00b5g once daily in moderate to severe COPD patients [Abstract]","volume":"138","author":"Fuhr","year":"2010","journal-title":"Chest"},{"issue":"3","key":"10.1002\/14651858.CD010509.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1378\/chest.11-0406","article-title":"Efficacy of aclidinium bromide 400 \u00b5g twice daily compared with placebo and tiotropium in patients with moderate to severe COPD","volume":"141","author":"Fuhr","year":"2012","journal-title":"Chest"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0079|cit79","unstructured":"NCT00868231 Efficacy of aclidinium bromide administered in chronic obstructive pulmonary disease (COPD) patients http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00868231"},{"issue":"4_Meeting abstr","key":"10.1002\/14651858.CD010509.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"691A","DOI":"10.1378\/chest.1389776","article-title":"Effects of aclidinium bromide in patients with chronic obstructive pulmonary disease: clinically significant improvements in health status in two 1-year studies","volume":"142","author":"Gelb","year":"2012","journal-title":"Chest"},{"issue":"12","key":"10.1002\/14651858.CD010509.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1016\/j.rmed.2013.07.001","article-title":"Long-term safety and efficacy of twice-daily aclidinium bromide in patients with COPD","volume":"107","author":"Gelb","year":"2013","journal-title":"Respiratory Medicine"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0082|cit82","doi-asserted-by":"crossref","unstructured":"Gelb A Tashkin D Make B Zhong X Garcia Gil E Caracta C Long-term safety of twice-daily aclidinium bromide in COPD patients: a one-year, double-blind study [Abstract] European Respiratory Society Annual Congress; Sep 1-5; Vienna 2012 376s [P2118]","DOI":"10.1164\/ajrccm-conference.2012.185.1_MeetingAbstracts.A2256"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0083|cit83","first-page":"A2256","article-title":"Long-term efficacy and safety of twice-daily aclidinium bromide in COPD patients: a one-year Study [Abstract]","volume":"185 (Meeting Ab","author":"Gelb","year":"2012","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0084|cit84","unstructured":"NCT01044459 Long-term safety, tolerability and efficacy of aclidinium bromide in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAS-MD-35) http:\/\/www.clinicaltrials.gov\/ct2\/show\/study\/NCT01044459"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0085|cit85","unstructured":"Tashkin D Gelb A Make B Zhong X Garcia Gil E Caracta C Long-term efficacy of twice-daily aclidinium bromide in COPD patients: a one-year study [Abstract] European Respiratory Society Annual Congress; Sep 1-5; Vienna 2012 528s [P2893]"},{"issue":"7","key":"10.1002\/14651858.CD010509.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"460","DOI":"10.5414\/CPP47460","article-title":"Safety and pharmacokinetics of single doses of aclidinium bromide, a novel long-acting, inhaled antimuscarinic, in healthy subjects","volume":"47","author":"Jansat","year":"2009","journal-title":"International Journal of Clinical Pharmacology and Therapeutics"},{"issue":"10","key":"10.1002\/14651858.CD010509.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1177\/0091270009336353","article-title":"Safety and pharmacokinetics of multiple doses of aclidinium bromide, a novel long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease, in healthy participants","volume":"49","author":"Jansat","year":"2009","journal-title":"Journal of Clinical Pharmacology"},{"issue":"6","key":"10.1002\/14651858.CD010509.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.rmed.2009.12.003","article-title":"Bronchodilatory effects of aclidinium bromide, a long-acting muscarinic antagonist, in COPD patients","volume":"104","author":"Joos","year":"2010","journal-title":"Respiratory Medicine"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0089|cit89","first-page":"210s [1299]","article-title":"Bronchodilator effects of aclidinium bromide a novel long-acting anticholinergic in COPD patients a phase II study [Abstract]","volume":"30 Suppl 51","author":"Joss","year":"2007","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0090|cit90","unstructured":"EUCTR2009-015901-38-DE Efficacy, safety and tolerability of two fixed-dose combinations of aclidinium bromide with two doses of formoterol fumarate compared with aclidinium bromide, formoterol fumarate and placebo all administered twice daily in stable, moderate to severe chronic obstructive pulmonary disease patients https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2009-015901-38"},{"issue":"4_Meeting Abstr","key":"10.1002\/14651858.CD010509.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"747A","DOI":"10.1378\/chest.1703061","article-title":"Dose-ranging study of two fixed-dose combinations of twice-daily aclidinium bromide plus formoterol in patients with moderate to severe COPD","volume":"144","author":"Kerwin","year":"2013","journal-title":"Chest"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0092|cit92","unstructured":"NCT01049360 Efficacy and safety study of two fixed-dose combinations of aclidinium bromide with formoterol fumarate compared with aclidinium bromide, formoterol fumarate and placebo (LAC-MD-27) http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01049360"},{"issue":"6","key":"10.1002\/14651858.CD010509.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1177\/0091270010374471","article-title":"Aclidinium bromide, a long-acting antimuscarinic, does not affect QT interval in healthy subjects","volume":"51","author":"Lasseter","year":"2011","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0094|cit94","unstructured":"Lasseter KC Aubets J Garcia GE Aclidinium bromide a novel long acting anticholinergic does not affect QT interval in healthy subjects [Abstract] American Thoracic Society International Conference; May 16-21; Toronto 2008 A655[#F54]"},{"issue":"2","key":"10.1002\/14651858.CD010509.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.pupt.2012.02.002","article-title":"Safety and pharmacokinetics of multiple doses of aclidinium bromide administered twice daily in healthy volunteers","volume":"25","author":"Lasseter","year":"2012","journal-title":"Pulmonary Pharmacology and Therapeutics"},{"issue":"Meeting Abstrac","key":"10.1002\/14651858.CD010509.pub2-BIB0096|cit96","first-page":"A1615","article-title":"Safety and pharmacokinetics of multiple doses of aclidinium bromide administered twice daily in healthy volunteers [Abstract]","volume":"183","author":"Lasseter","year":"2011","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"12","key":"10.1002\/14651858.CD010509.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1016\/j.rmed.2009.07.006","article-title":"Peak inspiratory flow through the Genuair inhaler in patients with moderate or severe COPD","volume":"103","author":"Magnussen","year":"2009","journal-title":"Respiratory Medicine"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0098|cit98","unstructured":"EUCTR2008-006886-10-DE A multiple dose, double blind, double-dummy, two-week three way cross-over, placebo-controlled clinical trial to assess the efficacy and safety of twice daily inhaled aclidinium bromide 400 \u00b5g compared to placebo and to an active comparator in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD) https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2008-006886-10"},{"issue":"Meeting Abstrac","key":"10.1002\/14651858.CD010509.pub2-BIB0099|cit99","first-page":"A4440","article-title":"Efficacy and safety of aclidinium bromide 400 {micro}g twice daily compared with placebo and tiotropium in patients with moderate to severe COPD [Abstract]","volume":"181","author":"Magnussen","year":"2010","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0100|cit100","unstructured":"EUCTR2005-005804-17-NL A single dose, double-blind, double-dummy, three period cross-over, placebo controlled clinical trial to assess the rate of onset of action of inhaled LAS 34273 200 \u00b5g compared to placebo and tiotropium 18 \u00b5g in patients with chronic obstructive pulmonary disease (COPD) http:\/\/apps.who.int\/trialsearch\/Trial.aspx?TrialID=EUCTR2005-005804-17-NL or https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2005-005804-17"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0101|cit101","unstructured":"NCT00435760 Clinical trial to assess rate of onset of bronchodilator action in severe stable chronic obstructive pulmonary disease (COPD) patients http:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT00435760"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0102|cit102","unstructured":"NCT00626522 Aclidinium\/formoterol fixed combination dose finding study http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00626522"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0103|cit103","unstructured":"NCT00706914 Comparison of aclidinium bromide and formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00706914"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0104|cit104","unstructured":"NCT01078623 Efficacy and safety of two fixed dose combinations of aclidinium bromide with formoterol fumarate (ALIGHT-COPD) http:\/\/clinicaltrials.gov\/show\/NCT01078623"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"386A","DOI":"10.1378\/chest.1825327","article-title":"Long-term safety of a fixed-dose combination of aclidinium bromide\/formoterol fumarate in patients with stable moderate to severe COPD","volume":"145","author":"Make","year":"2014","journal-title":"Chest"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0106|cit106","unstructured":"NCT01437540 Safety and tolerability of aclidinium bromide\/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (LAC) http:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT01437540"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0107|cit107","unstructured":"NCT01551888 Pharmacokinetic, safety and tolerability study of aclidinium\/formoterol fixed dose combination and formoterol in patients with moderate to severe chronic obstructive pulmonary disease (COPD) http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01551888"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0108|cit108","unstructured":"EUCTR2013-000116-14-HU A randomised, double-blind, double-dummy, active-controlled study evaluating the efficacy, safety and tolerability of twice-daily aclidinium bromide \/formoterol fumarate compared with twice-daily salmeterol\/fluticasone propionate for 24-weeks treatment in symptomatic patients with chronic obstructive pulmonary disease (COPD) https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2013-000116-14"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0109|cit109","unstructured":"NCT01908140 Study of aclidinium bromide\/formoterol fumarate compared with salmeterol\/fluticasone propionate in patients with chronic obstructive pulmonary disease (COPD) http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01908140"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0110|cit110","unstructured":"NCT01915784 Preference, satisfaction and ease of use of Genuair\u00ae (Pressair\u2122) and Breezhaler\u00ae (Neohaler\u2122) inhalers in patients with COPD http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01915784"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0111|cit111","unstructured":"NCT02038829 A dose-range finding study of SUN-101 in subjects with moderate to severe COPD (GOLDEN 6) http:\/\/clinicaltrials.gov\/ct2\/show\/NCT02038829"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0112|cit112","unstructured":"NCT02039050 Evaluation of long-acting muscarinic antagonists in COPD (MAN04) http:\/\/clinicaltrials.gov\/ct2\/show\/NCT02039050"},{"issue":"Meeting Abstrac","key":"10.1002\/14651858.CD010509.pub2-BIB0113|cit113","first-page":"A4464","article-title":"Safety and tolerability of aclidinium bromide administered intravenously and absolute bioavailability of inhaled aclidinium bromide in healthy subjects [Abstract]","volume":"181","author":"Ortiz","year":"2010","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0114|cit114","unstructured":"Ortiz S Flach S Caracta C Garcia Gil E Jansat J Absolute bioavailability of inhaled aclidinium bromide and safety and tolerability of aclidinium bromide administered intravenously in healthy subjects [Abstract] European Respiratory Society Annual Congress; Sep 18-22; Barcelona 2010 [P1180]"},{"issue":"5","key":"10.1002\/14651858.CD010509.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/j.1365-2125.2010.03622.x","article-title":"Activity of aclidinium bromide, a new long-acting muscarinic antagonist: a phase I study","volume":"69","author":"Schelfhout","year":"2010","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0116|cit116","unstructured":"Schelfhout VJ Joos GF Ferrer P Kannies F Luria X Richter K Activity of LAS34273, a new long acting anticholinergic antagonist, in COPD patients [abstract] American Thoracic Society 99th International Conference; May 16-21; Seattle 2003"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0117|cit117","first-page":"356S","article-title":"Bronchodilator\/broncho-protective effects of aclidinium bromide, a novel long-acting anticholinergic:a phase I study","volume":"30 Suppl 51","author":"Schelfhout","year":"2007","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0119|cit118","unstructured":"Efficacy and safety of three doses of aclidinium bromide compared to placebo and to an active comparator in chronic obstructive pulmonary disease (COPD) patients http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01120093"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0118|cit119","unstructured":"EUCTR2009-017380-42-DE Efficacy and safety of three doses of aclidinium bromide compared to placebo and to an active comparator all administered twice daily by inhalation in patients with stable moderate and severe chronic obstructive pulmonary disease (COPD) https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2009-017380-42"},{"issue":"3","key":"10.1002\/14651858.CD010509.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.pupt.2012.03.008","article-title":"A randomised, placebo- and active-controlled dose-finding study of aclidinium bromide administered twice a day in COPD patients","volume":"25","author":"Singh","year":"2012","journal-title":"Pulmonary Pharmacology and Therapeutics"},{"issue":"2","key":"10.1002\/14651858.CD010509.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.pupt.2013.01.001","article-title":"Corrigendum to \" A randomised, placebo- and active-controlled dose-finding study of aclidinium bromide administered twice a day in COPD patients\" [Pulm Pharmacol Ther 25 (3) (2012) 248-53]","volume":"26","author":"Singh","year":"2013","journal-title":"Pulmonary Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0122|cit122","first-page":"A172 [P256]","article-title":"Aclidinium bromide: a phase IIB, dose-finding study [Abstract]","volume":"66 Suppl 4","author":"Singh","year":"2011","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0123|cit123","unstructured":"NCT01385696 Study evaluating preference, satisfaction and ease of use of inhalers in chronic obstructive pulmonary disease (COPD) diagnosed patients http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01385696"},{"issue":"8","key":"10.1002\/14651858.CD010509.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1517\/17425247.2013.808186","article-title":"Preference, satisfaction and errors with two dry powder inhalers in patients with COPD","volume":"10","author":"Palen","year":"2013","journal-title":"Expert Opinion on Drug Delivery"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0125|cit125","first-page":"389s","article-title":"Preference, satisfaction and critical errors with Genuair\u00ae and HandiHaler\u00ae in patients with COPD","volume":"40 Suppl 56","author":"Palen","year":"2012","journal-title":"European Respiratory Journal"},{"issue":"5","key":"10.1002\/14651858.CD010509.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3109\/15412555.2010.510158","article-title":"Onset of effect of aclidinium, a novel, long-acting muscarinic antagonist, in patients with COPD","volume":"7","author":"Vestbo","year":"2010","journal-title":"COPD"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0127|cit127","first-page":"A167 [P212]","article-title":"Fast onset of effect of aclidinium bromide, a novel long-acting muscarinic antagonist, in patients with COPD [Abstract]","volume":"64 Suppl IV","author":"Vestbo","year":"2009","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0128|cit128","unstructured":"Vestbo J Vogelmeier C Creemers J Ribera A Garcia Gil E Rate of onset of action of aclidinium bromide, a novel, long-acting, muscarinic antagonist [Abstract] European Respiratory Society Annual Congress; Sep 12-16; Vienna 2009 [E4362]"},{"issue":"Meeting Abstrac","key":"10.1002\/14651858.CD010509.pub2-BIB0129|cit129","first-page":"A2430","article-title":"Aclidinium bromide improves exercise endurance and dynamic hyperinflation and decreases exertional dyspnoea in patients with moderate-to-severe COPD","volume":"187","author":"Beeh","year":"2013","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0130|cit130","unstructured":"Beeh KM Watz H Magnussen H Puente-Maestu L Jarreta D Caracta C Effects of aclidinium bromide on exercise endurance, dynamic hyperinflation, physical activity and exertional dyspnoea in patients with moderate to severe COPD [Abstract] European Respiratory Society Annual Congress, Sep 7-11; Barcelona 2013 636s [3035]"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0131|cit131","unstructured":"EUCTR2011-002665-38-DE A multiple dose, randomised, double-blind, placebo controlled, two period crossover clinical trial to assess the effect of aclidinium bromide 400 \u00b5g bid on exercise endurance in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD) https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2011-002665-38"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0132|cit132","unstructured":"NCT01471171 Efficacy and safety of aclidinium bromide 400 \u00b5g BID (twice a day) compared to placebo in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD) http:\/\/clinicaltrials.gov\/show\/NCT01471171"},{"issue":"Meeting Abstrac","key":"10.1002\/14651858.CD010509.pub2-BIB0133|cit133","first-page":"A2431","article-title":"Aclidinium bromide improves static lung function and hyperinflation in patients with moderate-to-severe COPD","volume":"187","author":"Watz","year":"2013","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0134|cit134","unstructured":"Watz H Beeh KM Magnussen H de Theresa L Jarreta D Caracta C Effect of aclidinium bromide on static lung function and hyperinflation in patients with moderate to severe COPD [Abstract] European Respiratory Society Annual Congress; Sep 7-11; Barcelona 2013 981s [4633]"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0135|cit135","unstructured":"NCT01636401 Efficacy and safety of 400 \u03bcg twice daily of aclidinium bromide vs. placebo when administered to patients with moderate to severe chronic obstructive pulmonary disease (COPD) http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01636401"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0136|cit136","unstructured":"NCT01966107 Evaluate the effect of aclidinium bromide on long-term cardiovascular safety and COPD exacerbations in patients with moderate to very severe COPD (ASCENT COPD) http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01966107"},{"issue":"1","key":"10.1002\/14651858.CD010509.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/1753465810381546","article-title":"An update on the efficacy and safety of aclidinium bromide in patients with COPD","volume":"5","author":"Alagha","year":"2011","journal-title":"Therapeutic Advances in Respiratory Disease"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0138|cit138","doi-asserted-by":"crossref","unstructured":"Alagha K Palot A Sofalvi T Pahus L Gouitaa M Tummino C Long-acting muscarinic receptor antagonists for the treatment of chronic airway diseases Therapeutic Advances in Chronic Disease 2014 85 98","DOI":"10.1177\/2040622313518227"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0139|cit139","unstructured":"Almirall Clinical trial results http:\/\/www.almirall.com\/webcorp2\/cda\/ImD_04_03.jsp?fMarc="},{"issue":"3","key":"10.1002\/14651858.CD010509.pub2-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"179","DOI":"10.7326\/0003-4819-155-3-201108020-00008","article-title":"Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society","volume":"155","author":"Qaseem","year":"2011","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0141|cit141","unstructured":"Hoyert DL Xu J Deaths: preliminary data for 2011 (National Vital Statistics Reports) http:\/\/www.cdc.gov\/nchs\/data\/nvsr\/nvsr61\/nvsr61_06.pdf"},{"issue":"5","key":"10.1002\/14651858.CD010509.pub2-BIB0142|cit142","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002309.pub2","article-title":"Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease","author":"Chong","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9","key":"10.1002\/14651858.CD010509.pub2-BIB0143|cit143","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009157.pub2","article-title":"Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease","author":"Chong","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD010509.pub2-BIB0144|cit144","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001744.pub2","article-title":"Domiciliary oxygen for chronic obstructive pulmonary disease","author":"Cranston","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD010509.pub2-BIB0145|cit145","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002990.pub2","article-title":"Self-management education for patients with chronic obstructive pulmonary disease","author":"Effing","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0146|cit146","unstructured":"United States Food Drug Administration (FDA) Drug approval package; Tudorza Pressair (aclidinium bromide) inhalation powder http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/202450Orig1s000TOC.cfm"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0147|cit147","unstructured":"Forest Pharmaceuticals, Inc. Subsidiary of Forest Laboratories, Inc http:\/\/www.forestpharm.com\/"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000320796","article-title":"Aclidinium bromide, a novel long-acting muscarinic antagonist (LAMA). New drugs and targets for asthma and COPD","volume":"39","author":"Gavald\u00e0","year":"2010","journal-title":"Progress in Respiratory Research"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0149|cit149","unstructured":"Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013 Global strategy for diagnosis, management and prevention of COPD http:\/\/www.goldcopd.org\/guidelines-global-strategy-for-diagnosis-management.html"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0150|cit150","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1146\/annurev.pathol.4.110807.092145","article-title":"The pathology of chronic obstructive pulmonary disease","volume":"4","author":"Hogg","year":"2009","journal-title":"Annual Review of Pathology: Mechanisms of Disease"},{"issue":"10","key":"10.1002\/14651858.CD010509.pub2-BIB0152|cit152","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008250.pub2","article-title":"Breathing exercises for chronic obstructive pulmonary disease","author":"Holland","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0153|cit153","unstructured":"Jones PW Rennard SI Agusti A Chanez P Magnussen H Fabbri L Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3098801\/ 10.1186\/1465-9921-12-55"},{"issue":"4","key":"10.1002\/14651858.CD010509.pub2-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1183\/09031936.00225511","article-title":"Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study","volume":"40","author":"Jones","year":"2012","journal-title":"European Respiratory Journal"},{"issue":"4","key":"10.1002\/14651858.CD010509.pub2-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s12325-013-0019-2","article-title":"Aclidinium bromide twice daily for the treatment of chronic obstructive pulmonary disease: a review","volume":"30","author":"Jones","year":"2013","journal-title":"Advances in Therapy"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"405","DOI":"10.2147\/COPD.S48967","article-title":"Comparative efficacy of aclidinium versus glycopyrronium and tiotropium, as maintenance treatment of moderate to severe COPD patients: a systematic review and network meta-analysis","volume":"8","author":"Karabis","year":"2013","journal-title":"International Journal of Chronic Obstructive Pulmonary Disease"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0157|cit157","unstructured":"Karakiulakis G Roth M Muscarinic receptors and their antagonists in COPD: anti-inflammatory and anti-remodeling effects http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3512336\/ 10.1155\/2012\/409580"},{"issue":"7","key":"10.1002\/14651858.CD010509.pub2-BIB0158|cit158","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009285.pub2","article-title":"Tiotropium versus placebo for chronic obstructive pulmonary disease","author":"Karner","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD010509.pub2-BIB0159|cit159","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003793.pub2","article-title":"Pulmonary rehabilitation for chronic obstructive pulmonary disease","author":"Lacasse","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1136\/bmj.332.7551.1202","article-title":"ABC of chronic obstructive pulmonary disease: pathology, pathogenesis, and pathophysiology","volume":"332","author":"MacNee","year":"2006","journal-title":"BMJ"},{"issue":"6","key":"10.1002\/14651858.CD010509.pub2-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1177\/1753465812463626","article-title":"The potential for aclidinium bromide, a new anticholinergic, in the management of chronic obstructive pulmonary disease","volume":"6","author":"Maltais","year":"2012","journal-title":"Therapeutic Advances in Respiratory Disease"},{"issue":"9","key":"10.1002\/14651858.CD010509.pub2-BIB0162|cit162","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006829.pub2","article-title":"Combined corticosteroid and long-acting beta2-agonist in one inhaler versus long-acting beta2-agonists for chronic obstructive pulmonary disease","author":"Nannini","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0163|cit163","unstructured":"National Institute for Health and Clinical Excellence Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care London: National Clinical Guideline Centre. http:\/\/guidance.nice.org.uk\/CG101\/Guidance\/pdf\/English"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0164|cit164","unstructured":"National Institute for Health and Clinical Excellence Chronic obstructive pulmonary disease, costing report, implementing NICE guidance http:\/\/guidance.nice.org.uk\/CG101\/CostingReport\/pdf\/English"},{"issue":"8","key":"10.1002\/14651858.CD010509.pub2-BIB0165|cit165","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002733.pub2","article-title":"Influenza vaccine for patients with chronic obstructive pulmonary disease","author":"Poole","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD010509.pub2-BIB0166|cit166","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001287.pub4","article-title":"Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease","author":"Poole","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD010509.pub2-BIB0167|cit167","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003902","article-title":"Oral theophylline for chronic obstructive pulmonary disease","author":"Ram","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0168|cit168","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2012"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2147\/COPD.S15524","article-title":"Profile of aclidinium bromide in the treatment of chronic obstructive pulmonary disease","volume":"6","author":"Sims","year":"2011","journal-title":"International Journal of Chronic Obstructive Pulmonary Disease"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"150","DOI":"10.2174\/1874306401206010150","article-title":"Aclidinium bromide: clinical benefit in patients with moderate to severe COPD","volume":"6","author":"Suppli Ulrik","year":"2012","journal-title":"The Open Respiratory Medicine Journal"},{"issue":"26","key":"10.1002\/14651858.CD010509.pub2-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1056\/NEJMra030415","article-title":"Management of chronic obstructive pulmonary disease","volume":"350","author":"Sutherland","year":"2004","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD010509.pub2-BIB0172|cit172","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001001.pub2","article-title":"Lung volume reduction surgery for diffuse emphysema","author":"Tiong","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0173|cit173","unstructured":"Abramson M Crockett AJ Dabscheck E Frith PA George J Glasgow N on behalf of Lung Foundation Australia and the Thoracic Society of Australia and New Zealand The COPD-X Plan: Australian and New Zealand guidelines for the management of chronic obstructive pulmonary disease. Version 2.35 2013 http:\/\/www.copdx.org.au\/"},{"issue":"12","key":"10.1002\/14651858.CD010509.pub2-BIB0174|cit174","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002999","article-title":"Smoking cessation for chronic obstructive pulmonary disease","author":"Meer","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD010509.pub2-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1177\/1753465811406001","article-title":"NVA237, a long-acting muscarinic antagonist, as an emerging therapy for chronic obstructive pulmonary disease","volume":"5","author":"Vogelmeier","year":"2011","journal-title":"Therapeutic Advances in Respiratory Disease"},{"issue":"3","key":"10.1002\/14651858.CD010509.pub2-BIB0176|cit176","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005374","article-title":"Oral corticosteroids for stable chronic obstructive pulmonary disease","author":"Walters","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"11","key":"10.1002\/14651858.CD010509.pub2-BIB0177|cit177","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001390.pub2","article-title":"Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease","author":"Walters","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD010509.pub2-BIB0178|cit178","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007891.pub2","article-title":"Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease","author":"Welsh","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0179|cit179","unstructured":"World Health Organization The global burden of disease: 2004 update http:\/\/www.who.int\/healthinfo\/global_burden_disease\/GBD_report_2004update_full.pdf"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0180|cit180","unstructured":"World Health Organization Global status report on noncommunicable diseases 2010 http:\/\/www.who.int\/nmh\/publications\/ncd_report2010\/en\/"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0181|cit181","unstructured":"World Health Organization Chronic obstructive pulmonary disease http:\/\/www.who.int\/respiratory\/copd\/en"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0182|cit182","unstructured":"World Health Organization COPD predicted to be third leading cause of death in 2030 http:\/\/www.who.int\/respiratory\/copd\/World_Health_Statistics_2008\/en\/index.html#"},{"key":"10.1002\/14651858.CD010509.pub2-BIB0183|cit183","unstructured":"World Health Organization International Clinical Trials Registry Platform (ICTRP) search portal http:\/\/apps.who.int\/trialsearch\/"},{"issue":"7-8","key":"10.1002\/14651858.CD010509.pub2-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1345\/aph.1S002","article-title":"Aclidinium bromide: an alternative long-acting inhaled anticholinergic in the management of chronic obstructive pulmonary disease","volume":"47","author":"Woods","year":"2013","journal-title":"The Annals of Pharmacotherapy"},{"issue":"7","key":"10.1002\/14651858.CD010509.pub2-BIB0185|cit185","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002991.pub3","article-title":"Inhaled corticosteroids for stable chronic obstructive pulmonary disease","author":"Yang","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD010509.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T16:36:57Z","timestamp":1721752617000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD010509.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Airways Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2014,9,19]]},"references-count":185,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2015,4]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd010509.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,19]]}}}